Patent ID: 7838290

Claim:
An isolated, CD133 positive human lineage negative hematopoietic stem cell population, which comprises human hematopoietic stem cells and endothelial progenitor cells, wherein the stem cell population is isolated by the steps of: (a) labeling a plurality of isolated human bone marrow monocytes with a panel of biotin-conjugated antibodies selective for lineage surface antigens CD2, CD3, CD4, CD11a, Mac-1, CD14, CD16, CD19, CD24, CD33, CD38, CD45RA, CD64, CD68, CD86, and CD235a; (b) removing monocytes that are positive for said lineage surface antigens from the labeled plurality of isolated human bone marrow monocytes produced in step (a) to form a lineage negative stem cell population; (c) labeling the lineage negative stem cell population with a CD133 antibody; and (d) recovering a population of human CD133 positive, lineage negative hematopoietic stem cells containing endothelial progenitor cells therefrom.